Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors

Diabetologia. 2012 Oct;55(10):2848-2849. doi: 10.1007/s00125-012-2635-9. Epub 2012 Jul 7.

Author

A J Scheen^{1

2}

Affiliations

¹ Department of Medicine, Division of Diabetes, Nutrition and Metabolic Disorders, CHU Liège, University of Liège, 4000, Liège, Belgium. andre.scheen@chu.ulg.ac.be.
² Department of Medicine, Unit of Clinical Pharmacology, CHU Liège, University of Liège, Liège, Belgium. andre.scheen@chu.ulg.ac.be.

PMID: 22772765
DOI: 10.1007/s00125-012-2635-9

No abstract available

Publication types

Letter

MeSH terms

Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / drug therapy*
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
Drug Therapy, Combination
Europe
Glycated Hemoglobin / metabolism
Humans
Hypoglycemic Agents / therapeutic use*
Metformin / therapeutic use*
Societies, Medical
Treatment Outcome
United States

Substances

Dipeptidyl-Peptidase IV Inhibitors
Glycated Hemoglobin A
Hypoglycemic Agents
Metformin